| Transcriptional signature primes human oral mucosa for rapid wound healing R Iglesias-Bartolome, A Uchiyama, AA Molinolo, L Abusleme, SR Brooks, ... Science translational medicine 10 (451), eaap8798, 2018 | 202 | 2018 |
| Assembly and activation of the Hippo signalome by FAT1 tumor suppressor D Martin, MS Degese, L Vitale-Cross, R Iglesias-Bartolome, JLC Valera, ... Nature communications 9 (1), 2372, 2018 | 145 | 2018 |
| Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4 Z Wang, VH Wu, MM Allevato, M Gilardi, Y He, J Luis Callejas-Valera, ... Nature communications 10 (1), 5546, 2019 | 132 | 2019 |
| Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase IB study SF Powell, KA Gold, MM Gitau, CJ Sumey, MM Lohr, SC McGraw, ... Journal of Clinical Oncology 38 (21), 2427-2437, 2020 | 100 | 2020 |
| Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas M Gilardi, Z Wang, M Proietto, A Chillà, JL Calleja-Valera, Y Goto, ... Molecular cancer therapeutics 19 (9), 1784-1796, 2020 | 94 | 2020 |
| Inhibition of mTOR signaling and clinical activity of rapamycin in head and neck cancer in a window of opportunity trial TA Day, K Shirai, PE O'Brien, MG Matheus, K Godwin, AJ Sood, ... Clinical Cancer Research 25 (4), 1156-1164, 2019 | 86 | 2019 |
| mTOR co-targeting strategies for head and neck cancer therapy Z Wang, JC Valera, X Zhao, Q Chen, J Silvio Gutkind Cancer and Metastasis Reviews 36, 491-502, 2017 | 74 | 2017 |
| HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers S Ren, DA Gaykalova, T Guo, AV Favorov, EJ Fertig, P Tamayo, ... Oncogene 39 (40), 6327-6339, 2020 | 72 | 2020 |
| ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy CI Aceves-Luquero, A Agarwal, JL Callejas-Valera, L Arias-González, ... PloS one 4 (7), e6124, 2009 | 56 | 2009 |
| Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC EM Galan-Moya, MA de la Cruz-Morcillo, ML Valero, JL Callejas-Valera, ... PloS one 6 (12), e28406, 2011 | 52 | 2011 |
| ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma L Arias-González, I Moreno-Gimeno, AR del Campo, SO Leticia, ... Neoplasia 15 (6), 649-IN17, 2013 | 51 | 2013 |
| mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model JL Callejas-Valera, R Iglesias-Bartolome, P Amornphimoltham, ... Carcinogenesis 37 (10), 1014-1025, 2016 | 44 | 2016 |
| c‐Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin‐based therapy EM Galan‐Moya, J Hernandez‐Losa, CI Aceves Luquero, ... International journal of cancer 122 (2), 289-297, 2008 | 41 | 2008 |
| Control of the epithelial stem cell epigenome: the shaping of epithelial stem cell identity R Iglesias-Bartolome, JL Callejas-Valera, JS Gutkind Current opinion in cell biology 25 (2), 162-169, 2013 | 38 | 2013 |
| E1a gene expression blocks the ERK1/2 signaling pathway by promoting nuclear localization and MKP up-regulation: implication in vH-Ras-induced senescence JL Callejas-Valera, J Guinea-Viniegra, C Ramírez-Castillejo, JA Recio, ... Journal of Biological Chemistry 283 (19), 13450-13458, 2008 | 25 | 2008 |
| A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers K Yamaguchi, R Iglesias-Bartolomé, Z Wang, JL Callejas-Valera, ... Oncotarget 7 (10), 10696, 2016 | 19 | 2016 |
| β2-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCC CT Lucido, JL Callejas-Valera, PL Colbert, DW Vermeer, WK Miskimins, ... Oncogenesis 7 (10), 81, 2018 | 16 | 2018 |
| E1a is an exogenous in vivo tumour suppressor FJ Cimas, JL Callejas-Valera, DC García-Olmo, J Hernández-Losa, ... Cancer Letters 399, 74-81, 2017 | 15 | 2017 |
| E1a promotes c-Myc-dependent replicative stress: implications in glioblastoma radiosensitization ML Valero, FJ Cimas, L Arias, P Melgar-Rojas, E García, ... Cell Cycle 13 (1), 52-61, 2014 | 14 | 2014 |
| MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells FJ Cimas, JL Callejas-Valera, R Pascual-Serra, J García-Cano, ... Oncotarget 6 (42), 44095, 2015 | 13 | 2015 |
